Significant hearing loss that would prevent cisplatin administration Patients must not have a clinically relevant hearing impairment >= grade Has experienced prior or ongoing hearing impairment due to chemotherapy or radiotherapy as defined by one of the following: \r\n* Society of Pediatric Oncology (SIOP) grade hearing loss\r\n* Subjective (patient-reported) hearing difficulties\r\n* Subjective (patient-reported) tinnitus Patients with hearing loss assessed to be primarily sensorineural in nature, requiring a hearing aid, or intervention (i.e. interfering in a clinically significant way with activities of daily living); a conductive hearing loss from tumor-related otitis media is allowed Significant pre-existing hearing loss, as defined by the patient or treating physician Patients requiring hearing aids or reporting hearing loss must have audiogram performed within days prior to step registration; if audiogram is performed, patient must not have hearing impairment >= Common Terminology Criteria for Adverse events (CTCAE) grade No signs of clinically significant hearing loss Clinically significant hearing impairment, as judged by the Principal Investigator. Grade >= sensorineural hearing loss COHORT I: No significant contraindications to cisplatinum chemotherapy (significant hearing loss, renal dysfunction or neuropathy) Cisplatin-ineligible as defined by at least one of the following:\r\n* Calculated creatinine clearance >= but =< mL/min (Cockcroft-Gault)\r\n* ECOG performance status of or greater\r\n* CTCAE v grade >= audiometric hearing loss Existing major organ dysfunction > Grade , with the exception of hearing loss, hematological status, kidney and liver function Existing severe major organ dysfunction, i.e., renal, cardiac, hepatic, neurologic, pulmonary, or gastrointestinal toxicity >= grade except for hearing loss, alopecia, anorexia, nausea, and hypomagnesemia from total parenteral nutrition (TPN), which may be grade Existing major organ dysfunction, i.e., renal, cardiac, hepatic, neurologic, pulmonary, or gastrointestinal toxicity >= grade , with the exception of hearing loss and hematologic toxicity Patients with greater than grade hearing loss Has clinically relevant hearing impairment > grade Existing severe major organ dysfunction, i.e., renal, cardiac, hepatic, neurologic, pulmonary, or gastrointestinal toxicity > grade except for hearing loss, alopecia, anorexia, nausea, hyperbilirubinemia and hypomagnesemia from total parenteral nutrition (TPN), which may be grade Documentation of pre-existing hearing deficits Existing major organ dysfunction > grade , with the exception of hearing loss and hematologic toxicity (defined as suppression of all subtypes of white blood cells [WBCs], red blood cells [RBCs], and platelets) Patients with >= grade sensorineural hearing loss at baseline may receive radiation alone or radiation with carboplatin Existing major organ dysfunction > grade , with the exception of hearing loss and myelosuppression (defined as suppression of all types of white blood cells [WBCs], red blood cells [RBCs] and platelets) Pre-existing bilateral sensorineural hearing loss at >dB at any frequency from -Hz as assessed by a comprehensive audiometric evaluation for patients receiving cisplatin. This criteria will not apply to patients receiving carboplatin. Severe major organ toxicity; specifically, renal, cardiac, hepatic, pulmonary, and gastrointestinal system toxicity should all be less than grade ; patients with stable neurological deficits (because of their brain tumor) are not excluded; patients with =< hearing loss are not excluded Normal auditory acuity: defined as a normal age-related audiogram without significant hearing loss. Symptomatic altered hearing > grade by NCI-CTCv criteria Peripheral neuropathy >= grade or clinically significant sensorineural hearing loss or tinnitus BLADDER: Subjects must be considered cisplatin ineligible as per treating physician due to renal dysfunction, hearing impairment, or co-morbidities Grade >= sensorineural hearing loss Hearing loss >= grade Significant hearing loss that would prevent cisplatin administration Patients who are ineligible to receive cisplatin:\r\n* Creatinine clearance of less than mL/minute, hearing loss of decibels (dB) at two contiguous frequencies, grade or higher peripheral neuropathy, or New York Heart Association class III or higher heart failure\r\n* Hearing test will not be routinely done, it will only be done if patients report hearing loss at baseline or during treatment Clinically significant sensorineural hearing impairment which may be worsened via cisplatin exposure (audiometric abnormalities without corresponding clinical deafness are not grounds for exclusion) Patients should have an audiogram at baseline, and patients with pre-existing hearing loss or hearing loss during treatment should be assessed frequently during cisplatin therapy Patients must not have a clinically relevant hearing impairment > grade Pre-existing hearing impairment Existing severe major organ dysfunction i.e., renal, cardiac, hepatic, neurologic, pulmonary, or gastrointestinal toxicity >= grade except for hearing loss, alopecia, anorexia, nausea, hyperbilirubinemia and hypomagnesemia from total parenteral nutrition (TPN), which may be grade Preexisting grade >= hearing loss > grade hearing loss or tinnitus COHORT II: Patients must not have >= grade hearing deficits Symptomatic altered hearing > grade by NCI-CTCv criteria Existing major organ dysfunction > grade , with the exception of hearing loss and hematologic toxicity (defined as suppression of all subtypes of white blood cells [WBCs], red blood cells [RBCs], and platelets) Preexisting grade >= hearing loss Hearing: a) No clinically significant hearing loss, defined in Section ., number . Patients with significant hearing loss are not eligible for study participation defined as hearing loss that affects everyday life and/or for which a hearing aid is required. Serum creatinine > . or upper limit or normal (ULN), CCL < cc/min, peripheral neuropathy > grade and/or frequency hearing loss that interferes with activities of daily living are contraindications to cisplatin but not to carboplatin Clinically significant hearing loss or ringing in the ears Severe major organ toxicity; specifically, renal, cardiac, hepatic, pulmonary, and gastrointestinal system toxicity should all be less than or equal to grade ; patients with stable neurological deficits (because of their brain tumor) are not excluded; patients with =< hearing loss are not excluded Severe sensorineural hearing loss greater or equal to grade Hearing loss that would preclude participating in telephone sessions (determined by brief hearing assessment administered by research staff at each National Cancer Institute Community Oncology Research Program [NCORP] component); individuals who can compensate for hearing loss through the use of a hearing device or telecommunication device for the deaf (TDD) phone, and through the use of such devices are able to communicate with the study therapist by telephone, will be included; if the therapist cannot communicate with the participant by telephone, the participant will be excluded Neither has a significant hearing impairment precluding intervention session participation Hearing loss that would preclude participating in interventions; adequate hearing to participate will be determined via: () response of no to the question [Do you have a hearing problem now?]; participants with hearing aids will be allowed to enroll as long as their hearing is adequate to hear the sounds on the study devices; if necessary, potential study participants will receive a brief test trial with the RESPeRATE device; if they indicate inability to hear the guiding tones, they will not be enrolled in the study Visual or hearing impairment that would prevent ability to engage in the telephone session or study materials Caregiver is deaf or has significant hearing impairment and thus cannot use the telephone Adequate vision and hearing for valid completion of study measures No significant hearing impairment that would prevent participation in sessions Patients with communication barriers (e.g., hard of hearing) Hearing level threshold =< dB at all frequencies in both ears to be evaluable for evaluation of pantoprazole's effect on cisplatin ototoxicity; patients with hearing loss can be enrolled but will not be evaluable for ototoxicity objective No hearing impairment Vision and hearing (eyeglasses and/or hearing aid permissible) sufficient for valid test administration and cooperation with examinations Hearing levels that interfere with following test instruction Are deaf or hearing-disabled. No hearing impairment in patient or partner Participant has a sensory impairment (vision, hearing) that prohibits completion of neurocognitive examination Uncorrected hearing impairments Severe hearing impairment that limits the ability to use audio-based guided imagery modules Prior history of hearing impairment Previous or existing pathology of the inner ear with or without hearing loss (i.e. sudden sensorineural hearing loss, Menieres disease, autoimmune inner ear disease) Having impairing hearing or speech Communication barriers (e.g. hard of hearing) Hearing loss greater than grade Subject has normal baseline auditory function, defined as ? dB from to Hz, in both ears and does not have a history of sensorineural hearing loss. Patents must have no contraindication to cisplatin chemotherapy including no clinically significant hearing loss unless willing to accept the potential of further loss of hearing, no symptomatic peripheral neuropathy Hearing and vision impairments that would prevent ability to complete consent, interviews, or sample collection Patients with hearing and/or visual impairments OR Patients with impaired hearing or speech; Reasonably able to listen to radio, television (without hearing impairment)